Sorry, you need to enable JavaScript to visit this website.
Home Science Areas of Focus Vaccines

The human body is constantly dealing with invaders. Most of the time they’re detected and destroyed before they can do any harm. 

But there are times when it’s not a fair fight. 

Throughout our history, viruses like smallpox and influenza have killed hundreds of millions of people. So when it was discovered that the body could be armed ahead of time to fight the invader by inoculation with a vaccine,it was hailed as a breakthrough. 

Since then, vaccines have repeatedly confirmed their place as one of the greatest public health advancements of all time. And their widespread use has resulted in the control, elimination, or near-elimination of many infectious diseases that were once pervasive and often fatal.  

At Pfizer, we have a long history in vaccine research and development, including a pivotal role in the eradication of polio and smallpox. Through the development of innovative delivery systems and technologies (the term often used is “novel vaccines”), we’ve created innovations for preventing deadly bacterial infections like those caused by S. pneumoniae and N. meningitidis. 

Today, more than at any time in history, people are benefiting from safe and effective vaccines to prevent infections and diseases. These injections have protected people of all ages, from newborns to seniors. 

However, our work is not done. Many viruses and bacteria still present a serious health risk, and so we continue to focus on research and development in new areas, with the goal of adding more approved vaccines to tackle pathogens.

When a patient has a serious infection, they may be treated with antibiotic or antiviral drugs that aid their body in fighting the pathogen. While these medicines can be effective, fighting an infection once it’s advanced and the patient is hospitalized is not as easy as as preventing it in the first place. 

Vaccines work by preparing the body’s immune system with a defense against the pathogen. The virus or bacterium is recognized, neutralized, and destroyed, often before it can spread. 

Our Vaccine Research and Development scientists are working to extend the benefits of vaccines into new areas. They are ushering in a new era of innovation for the prevention of disease, with a special focus on researching and developing vaccines for special populations such as maternal/neonatal, and vaccines intended to address hospital-acquired infections, and cancer. 

To help protect as many people as possible from life-threatening illness, we’re working to develop and distribute vaccines throughout the world. We’ve already seen that by channeling resources to the most promising public health opportunities, we can have an impact across all areas of life.

Our Vaccine Research & Development program includes an ongoing focus on the prevention of pneumococcal disease.

We’re also advancing vaccines for additional serious childhood,adolescent and adult infections, including meningococcal disease, influenza, Lyme disease,respiratory syncytial virus (RSV),and C difficile.

Recent breakthroughs in vaccine development are showing promise on many different fronts. Learn about our experience in vaccines—spanning more than a century,  the latest vaccines in the development pipeline, and more.

Millions of infants and young children in resource-limited countries are being protected from pneumococcal disease through private-public partnerships. 

Learn about our pledge to the developing world, how we’re driving innovation, and how we’re partnering with Gavi, the global vaccine alliance.

  • Pfizer is committed to working with the global health community to accelerate access to our vaccines in the world’s poorest countries. Learn more about our pledge under Gavi’s Advance Market Commitment.

    How We’re Helping Developing Countries

  • We’re creating and sustaining access to vaccination through the development of innovative technologies, formulations, and management systems that meet the challenges of the developing world. 

    More on Innovative Distribution 

  • Learn about new funding to support refugees and internally displaced people.

    How We’re Helping Refugees

Our Centers for Therapeutic Innovation collaborates with academic institutions and investigators to push forward great science, using the depth and breadth of the Pfizer enterprise to accelerate concepts into viable therapies with breakthrough potential for patients.

Find Out More About CTI

Revolutionary medicines have the power to enrich and extend life across many disease areas. Explore our latest innovations.

Rare Disease
View All Rare Disease

Explore all of our disease and condition-related resources to learn more about your diagnosis and treatment options. 

Gene Therapy
Duchenne Muscular Dystrophy 
Gaucher Disease
Growth Hormone Deficiency 
Sickle Cell 
Transthyretin Amyloidosis 

Internal Medicine
View All Internal Medicine

We’re developing therapies to treat, slow, or prevent disease progression and improve the quality of life for patients with obesity, type 2 diabetes, and cardiovascular and kidney diseases. 

Inflammation & Immunology
View All Inflammation & Immunology

We look for treatments that provide more than just symptom relief, in order to address the root cause of chronic inflammatory diseases at a molecular level

View All Vaccines

Vaccines are the single most important innovation in the science of health to significantly reduce the threat of diseases that were once widespread and oftentimes fatal. 

Pipeline & Clinical Trials 

View All Oncology

Cancer treatment needs to be transformed across the entire landscape to significantly improve the lives of cancer patients worldwide.

Biology into medicine
Global Impact

Anti Infectives
View All Anti Infectives

Anti-infectives are medicines that work to prevent or treat infections, including antibacterials, antivirals, antifungals, and antiparasitic medications. 

Antimicrobial Resistance 
AMR Prevention 
Antimicrobial Surveillance 
Antimicrobial Stewardship 
Our Commitment as a Global Leader 
Environmental Protection 

The medicines available today have taken an average of 12 years to develop. With dedication, creativity, and science, we can significantly decrease that time.

  • 00Phase 1
  • 00Phase 2
  • 00Phase 3
  • 00Registration
  • 00Total
Media Name: jean_beebe300x170.jpg

Vice President, Clinical Portfolio Leader, I&I Research Unit

Media Name: seng_cheng300x170.jpg

Senior Vice President & Chief Scientific Officer, Rare Disease

Media Name: nanette_cocero300x170.jpg

Global President, Vaccines, Pfizer Biopharmaceuticals Group

Media Name: Olivier_Dirat_300x170px.jpg

Associate Research Fellow and Group Leader, Chemical Development Active Pharmaceutical Ingredients

Media Name: jeff_settleman300x170.jpg

Chief Scientific Officer

Media Name: k_beaverson300x170.jpg

Executive Director, Patient Advocacy Lead

Media Name: Kendra_Bence_300x170px.jpg

Executive Director, Metabolism

Media Name: binks300x170.jpg

Vice President, Clinical Research

Media Name: Julie_Brooks_300x170px.jpg

Postdoctoral Fellow

Media Name: christian_czech300x170.jpg

Senior Director, Biology and Nice Site Lead

Media Name: jeremy_d_gale300x170.jpg

Vice President and Clinical Portfolio Leader

Media Name: grimwood300x170.jpg

Executive Director, Head of Portfolio, Strategy & Operations

Media Name: GRUBER BILL 300x170.jpg

Senior Vice President of Pfizer Vaccine Clinical Research and Development


Chief Medical Officer and Head of Worldwide Medical & Safety

Media Name: K-Jansen_300x170px.jpg

Senior Vice President, Head of Vaccine Research and Development

Luis Jodar bio pic

SVP & Chief Medical Officer, Pfizer Vaccines

Media Name: Nicholas_Kitchin_300x170px.jpg

Senior Director

Media Name: Jennifer_Lafontaine_300x170px.jpg

Senior Director, Oncology Medicinal Chemistry Synthesis and Analytical Group

Media Name: LaRosa_21_300x170.jpg

Vice President, Head of Scientific Research

Media Name: Carolyn_Leverett_300x170px.jpg

Principal Scientist, Oncology Medicinal Chemistry

Media Name: clark_pan_300x170.jpg

Vice President, Gene Therapy and Discovery Biology


Vice President, Rare Neurology and Discovery Biology


Senior Vice President and Chief Scientific Officer, Internal Medicine Research Unit

Media Name: Ravi_Shanker_300x170px.jpg

Senior Research Fellow, Pharmaceutical Sciences

Media Name: Bruce_Thompson_300x170px.jpg

Sr. Principal Scientist, Biotherapeutics Pharmaceutical Sciences

Media Name: Fabien_Vincent_300x170px.jpg

Associate Research Fellow, Hit Discovery and Lead Profiling

Media Name: thomas_a_wynn300x170.jpg

Vice President, Discovery

Media Name: bei_zhang_300x170.jpg

Vice President, Metabolic Research

Learn more about the process of joining a clinical trial and find a trial near you.

Go to Pfizer Clinical Trials Site